Prevention of COVID-19 with oral vitamin D supplemental therapy in essential healthcare teams (PROTECT): protocol for a multicentre, triple-blind, randomised, placebo-controlled trial

Francine Monique Ducharme 1, Cécile Tremblay, Shirin Golchi, Banafsheh Hosseini, Cristina Longo, John H White, Decio Coviello, Caroline Quach, Louis-Georges Ste-Marie, Robert W Platt

ABSTRACT

Introduction In the COVID-19 pandemic, healthcare workers (HCWs) were at high risk of infection due to their exposure to COVID infections. HCWs were the backbone of our healthcare response to this pandemic; every HCW withdrawn or lost due to infection had a substantial impact on our capacity to deliver care. Primary prevention was a key approach to reduce infection. Vitamin D insufficiency is highly prevalent in Canadians and worldwide. Vitamin D supplementation has been shown to significantly decrease the risk of respiratory infections. Whether this risk reduction would apply to COVID-19 infections remained to be determined. This study aimed to determine the impact of high-dose vitamin D supplementation on incidence of laboratory-confirmed COVID-19 infection rate and severity in HCWs working in high COVID incidence areas.

Methods and analysis PROTECT was a triple-blind, placebo-controlled, parallel-group multicentre trial of vitamin D supplementation in HCWs. Participants were randomly allocated in a 1:1 ratio in variable block size to intervention (one oral loading dose of 100,000 IU vitamin D3 + 10,000 IU weekly vitamin D3) or control (identical placebo loading dose + weekly placebo). The primary outcome was the incidence of laboratory-confirmed COVID-19 infection, documented by RT-qPCR on salivary (or nasopharyngeal) specimens obtained for screening or diagnostic purposes, as well as self-obtained salivary specimens and COVID-19 seroconversion at endpoint. Secondary outcomes included disease severity; duration of COVID-19-related symptoms; COVID-19 seroconversion documented at endpoint; duration of work absenteeism; duration of unemployment support; and adverse health events. The trial was terminated prematurely, due to recruitment difficulty.

Ethics and dissemination This study involves human participants and was approved by the Research Ethics Board (REB) of the Centre hospitalier universitaire (CHU) Sainte-Justine serving as central committee for participating institutions (#MP-21-2021-3044). Participants provided written informed consent to participate in the study before taking part. Results are being disseminated to the medical community via national/international conferences and publications in peer-reviewed journals.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This trial was designed as a hybrid study enabling partially or totally remote screening, randomisation, follow-up, as well as outcome documentation by use of home capillary blood and saliva sampling, visits conducted by videoconference, monitoring by electronic reminders and questionnaires, and communication by phone, text messaging or emails.

⇒ The trial used a pragmatic subject selection and easily applicable intervention to maximise subsequent implementation in practice and selected a primary outcome, the risk of laboratory-confirmed infection, that would likely change practice.

⇒ A single loading dose followed by regular doses have been shown to lead to rapid and sustained increase in serum level of 25-hydroxyvitamin D and ensure adequate group separation, both properties desired in the context of a rapidly expanding epidemic while facilitating adherence in exhausted front-line health workers.

⇒ Given the uncertainty in the progression of the infection rate, the use of a Bayesian adaptive design allowed for adaptations (early stopping or prolongation of duration of follow-up) at the interim analysis according to the projection of infection rates. Although the trial aimed for high-intensity recruitment, the delay in setting up a remote study in the context of the pandemic, combined with high use of vitamin D and successful vaccination program in healthcare workers, resulted in severe recruitment difficulty and early stopping of the trial for futility.

Trial registration number https://clinicaltrials.gov/ct2/show/NCT04483635.
COVID-19 pandemic. It was therefore a public health priority to develop strategies to decrease the risk and severity of COVID-19 in this vulnerable population. Indeed, this was a rising concern as HCWs were over-represented in terms of infections (3.8% of infected individuals in Wuhan, China, 10% in Italy and 12% in Spain, 10–20% in USA) and perhaps severity. Working in long-term care facilities (LTCF) and with aerosol generating medical procedures (e.g. hospitals) further increased the risk (OR: 2.3). The risk of reporting COVID-19 infection in front-line HCWs, defined as those in direct contact with patients, was 10-fold greater than the general population at the beginning of the pandemic (HR = 11.61). Recent research also indicated that HCWs who were black, Asian or other minority ethnic populations, had a higher likelihood of contracting COVID-19. Compared with those unexposed to patients with COVID-19, the risk was twofold to fivefold higher in HCWs exposed to suspected (HR = 2.39) or confirmed (HR = 4.83) COVID-19 cases, even with adequate personal protection equipment (PPE). Although infections may have been due to contact with infected patients, community-acquired disease or family acquired disease, cases were rapidly emerging from cross-infection with asymptomatic infected HCWs.

Vitamin D is an immunomodulator micronutrient, and its levels in the body may vary due to diet and environmental conditions. Vitamin D insufficiency had been associated with increased risk of respiratory infections, and possibly COVID-19, asthma exacerbations and acute respiratory distress syndrome, among others. Optimal pro-immune and anti-inflammatory impacts likely occur at 25-hydroxyvitamin D (25OHD) levels above 75 nmol/L (30 ng/mL). In a systematic review of 25 randomised controlled trials (RCTs) of 11,321 individuals, daily/weekly vitamin D supplementation decreased by 19% the rate of acute respiratory infections (two-step analysis; OR 0.81, 95% CI 0.72 to 0.91), with a stronger effect in subjects with baseline 25OHD<25 nmol/L. Whereas subgroup analyses suggested a protective effect, primary in individuals receiving daily or weekly vitamin D supplement, and not in those with bolus, other important differences in population (e.g. malnutrition), age (infant), chronic disease (e.g. asthma, chronic obstructive pulmonary disease) and type of infection (e.g. bacterial) could have contributed to the apparent lesser effect. Of interest, vitamin D supplementation significantly reduced the rate of severe exacerbations (i.e., requiring rescue systemic corticosteroids), a condition associated with airway inflammation, with no impact according to bolus use or not. Vitamin D supplementation was also found to be associated with a decreased load of rhinovirus (common cold), consistent with an increased antiviral immune response.

A systematic review and several studies reported an inverse association between serum vitamin D levels and COVID-19 severity, inpatient mortality, as well as serum levels of C reactive protein (CRP) and lymphocyte percentage. These findings suggested that vitamin D status was linked with the severity and mortality of COVID-19 infection in the general population, particularly in severe COVID-19 cases. Whether vitamin D could have prevented or lessened infection and/or the inflammatory response associated with COVID-19 remained to be explored. At the time of funding (June 2020) and study initiation (February 2021), no other primary prevention trials were published. Since then, one positive and two negative trials testing different vitamin D interventions as primary prevention were published.

The vitamin D receptor is expressed on innate and adaptive immune cells which also synthesise the active metabolite 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃); thus, vitamin D could strengthen innate and adaptive cellular immunity by increasing local production of antimicrobial peptides, decreasing secretion of pro-inflammatory cytokines, inhibiting dendritic cell activation, suppressing T helper cell type 1 response, and promoting T regulatory cells induction. These cellular effects are crucial for host responses against infection and can reduce the survival and replication of respiratory viruses. 1,2,9,25 1,25(OH)₂D₃ is also produced locally in bronchial epithelial cells and downregulates inflammatory cytokines (e.g. interleukin-8) and chemokines (e.g. leucocyte attracting CXCL10) expression from stimulated cells.

The protocol of a placebo-controlled parallel-group triple-blind RCT to explore the impact of vitamin D₃ supplementation on reducing the risk and severity of laboratory-confirmed COVID-19 infection in HCWs is described here, as per Standard Protocol Items: Recommendation for Intervention Trials guidelines (online supplemental file 1). After funding, but prior to the start of recruitment, the protocol underwent four amendments (eight protocol versions) in view of the rapidly evolving science, multiple challenges faced with conducting a large-scale COVID-19 trial of high-risk HCWs during the pandemic, including difficulty in obtaining large-scale supplies, as well as favourable pilot results of two novel technologies (table 1). These original and final (V.1.8, 18 January 2021) protocol versions are described below. The trial was initiated but stopped prematurely due to recruitment difficulty.

Objectives
The primary research question was whether one oral dose of 100000 IU vitamin D₃ (administered at baseline) plus weekly supplement of 100 000 IU vitamin D₃ could decrease the risk of laboratory-confirmed COVID-19 infection, versus placebo, in front-line HCWs in high COVID-19 incidence areas.

Additionally, the study aimed to examine if, compared with placebo, the vitamin D intervention reduced: (1) Illness severity, (2) Symptom duration, (3) Work absenteeism and (4) Unemployment among front-line HCWs in high COVID-19 incidence areas. This study was to also assess various exploratory outcomes.

Hypothesis
We hypothesised that compared with placebo, vitamin D supplementation would decrease the incidence of
**Table 1: Study amendments and notifications**

<table>
<thead>
<tr>
<th>Version number</th>
<th>Clinical trial application (CTA)</th>
<th>Investigational testing authorisation (ITA)</th>
<th>Changes</th>
<th>Description</th>
<th>Submitted</th>
<th>Approved</th>
<th>Submitted</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>V.0.0 11-05-2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V.1.0 23-08-2020</td>
<td></td>
<td></td>
<td>Eligibility</td>
<td>Outcomes and covariates</td>
<td>23 August 2020</td>
<td>16 September 2020</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Amendment 1 V.1.1 23-10-2020</td>
<td></td>
<td>Clarification of the NADAL COVID-19 IgG/IgM rapid test (Teracero Pharma, Lachine, Canada) on capillary whole blood as the rapid serology test to exclude prior infection (following pilot comparative study).</td>
<td></td>
<td></td>
<td>23-10-2020 (CTA-A) *</td>
<td>02 November 2020</td>
<td>23 October 2020</td>
<td>14 November 2020</td>
</tr>
<tr>
<td>Amendment 2 V.1.2 to V.1.4 V.1.5 27-11-2020</td>
<td></td>
<td>Removal of saliva sample every two weeks for COVID-19 by RT-qPCR analysis due to supply problem with 50mL Falcon centrifuge tube caused by a global plastics shortage combined with unacceptable delay for public tender for a contract with courier service for biological samples sent every 2 weeks.</td>
<td></td>
<td></td>
<td>27-11-2020 (CTA-A) *</td>
<td>30 November 2020</td>
<td>23 November 2020 (TASSO-SST and NADAL)</td>
<td>2 December 2020</td>
</tr>
<tr>
<td>Amendment 3 V.1.6 and V.1.7 12-12-2020</td>
<td></td>
<td>Exclusion of healthcare workers who have received the COVID-19 vaccine prior to enrolment.</td>
<td></td>
<td></td>
<td>12 December 2020 (CTA-A) *</td>
<td>16 December 2020</td>
<td>12 December 2020 (TASSO-SST and NADAL)</td>
<td>23 December 2020</td>
</tr>
</tbody>
</table>

Continued on July 2, 2023 by guest. Protected by copyright.
laboratory-confirmed symptomatic COVID-19 infection by 20% in front-line HCWs working in high COVID-19 incidence area.

**METHODS AND ANALYSIS**

**Study design**

PROTECT was a pragmatic 16-week, triple-blind, placebo-controlled, parallel-group, randomised trial comparing supplemental vitamin D₃ and placebo in HCWs with the possibility of extending the study follow-up up to 24 weeks, depending on infection rate progression during an interim analysis (figure 1).

**Participants**

HCWs (ie, physicians, allied HCWs, orderlies, etc) were eligible if they: (1) Were aged ≥18 years and <70 years old; (2) Were authorised to practice in Quebec; (3) Were working or scheduled to work over the next 16 weeks in a setting at high risk of contact with COVID-19 infected individuals, particularly (but not only) those involved with aerosol-generating medical procedures in hospitals and/or caring for patients in LTCF; (4) Were working in high COVID-19 incidence areas in the greater Montreal area and surroundings; (5) Were covered by the provincial universal public health insurance (Régie de l’assurance-maladie du Québec (RAMQ)) for medical services and hospitalisations; (6) Had a personal email or phone (to which to send reminders and questionnaire by email or text messages); (7) Had a fixed address (to which to send the material) in the greater Montreal or surrounding areas.

HCWs were excluded if they met any of the following criteria: vitamin D supplementation (cholecalciferol or calcitriol) intake >400 IU/day (or >12,000 IU/month) in the past 3 months; intention to take >400 IU/day during the study period; suspected or previously documented COVID-19 infection; history of nephrolithiasis, hypercalcaemia, hyperparathyroidism, granulomatosis disease (eg, tuberculosis, sarcoidosis), renal failure, or active cancer; current intake of medications that may cause hypercalcaemia such as lithium, teriparatide or digoxin; anticipated prolonged absence from work during the study period (ie, pregnancy); anticipated difficult follow-up; enrolment in a concurrent interventional randomised trial; have already received the vaccine against COVID-19. Participation in this trial did not preclude subsequent enrolment in a COVID-19 therapeutic (but not preventive) trial, which would be documented.

**Study intervention**

Participants in the intervention group received 100,000 IU vitamin D₃ (cholecalciferol) at randomisation followed by a weekly dose of 10,000 IU vitamin D₃ for 16 weeks. Participants in the control groups received an identical placebo bolus followed by placebo weekly supplement for 16 weeks. Sufficient supply was provided for 24 weeks, in case of prolongation study based on the interim analysis. Participants in both groups were asked to take the study intervention with their most copious meal. Treatment of comorbidities was permitted. Vitamin D intake up to 400 IU per day was allowed.

**Randomisation**

Randomisation was implemented using a computer-generated random list stratified by one of 11 workplaces (Centre Hospitalier Universitaire (CHU)) or health region (Centre Intégré Universitaire de Santé et Services Sociaux (CIUSSS) or Centre Intégré de Santé et Services Sociaux (CISSS)). HCWs were allocated (1:1) using permuted block randomisation to enhance concealment. Group allocation codes for each
stratum was held in a secure location with restricted access by the Central Pharmacy and Data Management.

**Patient and public involvement**
Participant burden of research measures was ascertained using feedback from patients prior to study participation. Patients were not involved in study design, recruitment of participants or conduct of the study.

**Outcomes**

**Primary outcome**
The original primary outcome, incidence of laboratory-confirmed COVID-19 infection, was originally based on (1) bi-monthly self-obtained mid-turbinate nasopharyngeal (NP) swabs, complemented by (2) NP swabs obtained clinically for screening or diagnostic purposes throughout the study, both analysed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) approved by Health Canada. Faced with the unexpected cancellation of our large order of Falcon tubes to collect saliva sample for qPCR, combined with the unacceptable additional delay for a public tender to securing a contract with a private courier service, and in view of the uniform protocol for screening symptomatic or COVID-19-exposed HCWs throughout the Province of Quebec.
and the reliability of IgG serology, we decided to forgo the twice-monthly saliva sampling for qPRC analysis. The revised definition of the primary outcome became the incidence of laboratory-confirmed COVID-19 infection, documented by RT-qPCR based on salivary (or NP) specimens (1) Obtained for screening or diagnostic purposes throughout the study and (2) Self-obtained salivary specimens obtained at endpoint as well as (3) COVID-19 IgG seroconversion at endpoint (in COVID-unvaccinated individuals: ≥15 UA on the anti-SARS-CoV-2 IgG Diasorin on Liaison XL platform; in COVID-vaccinated individuals: ≥1.40 index (specimen/calibrator (S/C)) on the anti-N SARS-CoV-2 IgG on ARCHITECT platform from Abbott Core Laboratory Total Solution)

**Secondary outcomes**

1. **Distribution of disease severity** on a five-category ordinal scale (asymptomatic; mild (managed at home); moderate (hospitalisation without supplemental oxygen); severe (oxygen supplementation); critical (mechanical ventilation/death)), (self-reported, RAMQ); (2) **Duration of COVID-19 positivity** (between first COVID+ to first COVID− test) revised to duration of COVID-19-related symptoms in individuals with laboratory confirmation of COVID infection, (self-reported on diary); (3) **COVID-19 IgG seroconversion** documented at endpoint (see above); (4) **Duration of work absenteeism** (self-reported, medical records or human resources databases); (5) **Duration of unemployment support** (human resource databases); (6) **Adverse health events** (AHEs) (self-reported). Several **exploratory outcomes** pertained to the: incidence of postacute and chronic symptoms; long-term (1 year) morbidity and work absence related to COVID-19; change in gene expression of angiotensine converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in saliva cells; change in inflammatory markers (ie, CRP), immune response postvaccination; other viral infections; and genetic markers (including changes in gene expression).

**Study procedures**

To facilitate the recruitment of participants, this study was conceived as a hybrid trial enabling partially or totally remote trial participation including screening, randomisation, follow-up and end-of-study visit.

**Prescreening**

Advertisements were placed in health institutions, newspapers, social media and online, where participants were invited to complete an online prescreening form, read and download the consent forms; and if eligible and interested, to book a virtual screening appointment (via a secured videoconferencing platform) with a research team who would confirm eligibility, explain the study, obtain informed consent, and schedule a virtual or inperson randomisation visit.

**Screening**

At the virtual screening visit by videoconferencing, research coordinators completed with the individual a more extensive eligibility questionnaire, which included additional questions about: anticipated work exposure over the next 16 weeks to COVID-infected or suspected individuals and to high-risk medical procedures; work place (Centre hospitalier universitaire de Montréal (CHUM) or CHU Sainte-Justine) or health region (CIUSSS or CISSS), serving as randomisation stratum; prior laboratory-confirmed or physician-suspected COVID-19 infection; assessment of the likelihood of prior/current, yet undocumented, COVID-19 infection using the five-item questionnaire developed by Menni et al (score >0.50 interpreted as high likelihood of prior infection); and finally, the comfort level with the study design and procedures, including saliva and capillary blood sampling self-collection demonstrated by instructional videos. Eligible and consenting individuals electronically signed an online consent form (with the signed Portable Document Format (PDF) consent form automatically emailed to participants). Then, two additional questionnaires were completed online with the research coordinators namely: (1) The baseline questionnaire collecting information about household, ethnicity, part-time versus full-time work, personal health, skin colour (measured with the Fitzpatrick Scale), concomitant medications or supplements, and (2) The nominative Case Report Form (CRF) collecting demographic information essential to opening a medical and pharmaceutical research record (ie, public health insurance number, allergies) and maintaining contact with the research team throughout the study (preferred means to receive electronic reminders/questionnaires and to be notified of positive test results; address to receive study material or for biological sample pick-up; and next-of-kin contact in case of inability to respond to questionnaire due to illness), and to document work absence (employee number).

Finally, at the screening visit, the participant was asked to choose an appointment for a virtual (via a secured videoconferencing platform) or inperson randomisation visit at one of several locations. To help select their preferred visit format, videos of key procedures (such as home blood collection) were shown. An inperson randomisation visit was mandatory only in participants with a significant likelihood of a current or past undocumented COVID-19 infection (Menni Score>0.5) in order to receive the rapid COVID-19 serology test, prior to randomisation.

**Preparation and shipment of study drug by research pharmacy**

The list of new participants approved by one of the PIs was sent daily by email to the CHUM research team to be open a medical chart and send an electronically signed prescription for the study medication, to the research pharmacy for preparation of study drug.

Prior to randomisation, a list of all consenting and eligible participants was automatically sent every night to the one of the co-principal investigators (FMD or CT) who reviewed screening and baseline questionnaires to approve or refuse study entry and electronically signed
their decision. The daily list of new approved participants was sent electronically daily to the CHUM research team. Medical and pharmaceutical records were opened and an electronically signed prescription for the study medication sent to the research pharmacy for preparation of study drug for a given target date.

To enable remote randomisation, the randomisation took place about 1 week prior to the randomisation visit to allow enough time for the preparation and shipment of patient-specific study supplement to the research team and, in turn, the shipment of the study supplement and all materials required for the randomisation visit by the research team to the participant.

**Randomisation visit**

Seventy-two hours and 24 hours prior to, and at, the randomisation visit, participants were screened by questionnaire for recent travel, symptoms suggestive of SARS-CoV-2 infection, or exposure to COVID-19 infected individuals. Those who responded positively were asked to get tested, notify their institutional health service, and await end of quarantine and/or confirmed negative test to reschedule the randomisation visit.

Randomisation visit (week 0) was performed *in person* (60 min) or *remotely* (90 min), depending on the availability and preference of participants as well as their likelihood of a past COVID-19 infection.

*In person* visits were conducted—by appointment only—in designated rooms with restricted access. The research coordinators wore PPE; all procedures, from participant arrival to departure, were approved by the institutional Infection Control and Safety committee. The *in person* visit entailed (1) Ascertainment of the signed consent form, (2) Capillary blood sample collection to perform NADAL COVID-19 IgG/IgM rapid test (Teracero Pharma, Lachine Canada), (3) Venous blood sample collection for baseline serum 25(OH)D and SARS-CoV-2 IgG serology analyses and if genetic consent, DNA; (4) Viewing of the saliva collection video and instruction pamphlet, (5) Collection of the first specimen under supervision, (6) A final verification of the eligibility and exclusion criteria; (7) Randomisation; (8) Oral administration of 100,000 IU vitamin D₃ or an identical placebo, and (9) Distribution of the study material including study supplement, saliva sampling kit for end of study, biohazard and sampling bag, and, if a remote visit was anticipated at endpoint, capillary blood collection kits (TASSO-SST device, Tasso Inc., Seattle, USA). Any patient with a positive NADAL COVID-19 IgM/IgG rapid test serology test were excluded prior to randomisation.

The *remote* randomisation visit, conducted by videoconference, was similar to the *in person* randomisation visit with the following additions: (A) Viewing of the capillary blood collection video and instructional pamphlet; (B) Remote capillary sampling under guidance using the TASSO-SST device (Tasso Inc., Seattle, USA); (C) Viewing of the saliva collection video and instructional pamphlet (OG-600 Oragene DNA Collection Kit, DNA Genotek, Ottawa, Canada); (D) Remote DNA salivary sampling under guidance; (E) Preparation of biological samples for shipment with phase change and insulated envelopes under guidance and (F) Organising collection of biological specimens by approved courier service to respective laboratories. Note that a Nadal serology test was not conducted remotely.

**Follow-up**

Participants received *weekly electronic (SMS or email)* reminders to take their weekly study supplement intake; health status including recent COVID-19 related exposure, symptoms or testing; AHEs or new comorbidities; change in concomitant medications or supplement intake; work status (active duty, quarantined, holiday, sick) and work setting (emergency department, intensive care unit, etc.); as well as expected/recent COVID-19 vaccination (date and vaccine name) if any; the latter question served to enable timely shipment of materials for additional sampling prior to vaccination, as COVID-19 vaccination was permitted during the study. In participants who planned to get vaccinated during the study, three additional blood, and one additional saliva, samplings, either *on-site* or *remotely*, were planned including: saliva (for COVID-19 qPCR analysis) and blood (for SARS-CoV-2 anti-S IgG serology) sampled prior to vaccination, a blood sample (for SARS-CoV-2 anti-S and anti-N IgG serology) collected just prior to the second vaccine dose, and a blood sample (for SARS-CoV-2 anti-S and anti-N IgG serology) collected 1 month after second vaccine dose and endpoint. Regardless of their vaccination status, participants were asked to continue taking the weekly study supplement and complete the bi-monthly questionnaire until the end of the study. If questionnaires were not completed within 2 days of the target date, the research coordinator reached out to the participant to complete the information.

**End-of-study visit**

An end-of-study visit was conducted either *in person* (60 min) or remotely (90 min), depending on the availability and preference of participants and likelihood of a current COVID-19 infection. The *in person* end-of-study visit entailed the collection of a (1) Venous blood sample for serum 25(OH)D and SARS-CoV-2 anti-S IgG serological results and in vaccinated participants a SARS-CoV-2 anti-N IgG serology, (2) Capillary blood sample to perform the NADAL COVID-19 IgG/IgM rapid test, (3) A saliva sample for SARS-CoV-2 qPCR analysis as well as guessing of allocation and return of the study supplement bottle to assess adherence and any unused material.
The remote end-of-study visit conducted via videoconference entailed the same procedures as the in-person end-of-study visit with one exception: the self-collection of a capillary (instead of venous) blood using TASSO-SST devices (for the serum 25(OH)D and SARS-CoV-2 anti-S with/without anti-N serology). Individuals were guided into self-performing the pinprick capillary method to perform the NADAL COVID-19 IgG/IgM rapid test and return of biological samples and materials by prepaid approved courier.

**Covariates**

Several covariates that could act as confounders or interaction variables in the magnitude of effect associated with the intervention were documented: namely: baseline serum 25OHD level; smoking; concomitant supplements or drug(s) that can alter calcium or vitamin D absorption or metabolism such as diuretics and antiepileptics (reported at baseline and every 2 weeks); skin colour (documented at baseline); obesity (documented by height and weight (body mass index (BMI)) at baseline); other comorbidities (i.e., diabetes, hypertension, etc) that may affect the severity of COVID-19 infection and receipt of a COVID-19 vaccine (documented by verbal report bi-monthly). All external (governmental and institutional) databases were to be obtained 3 months before, and up to 16 months following, randomisation (as well as 12 months after then study endpoint).

**During an event**

During COVID-19-related symptoms or documented SARS-CoV infection, participants were instructed to complete a daily symptom diary from date of onset of symptoms or positive test, until 2 days with no symptoms or 14 days if asymptomatic.

**Risk management**

Clinical and biochemical AHEs were monitored throughout the study and reported for all patients at the end of the study. No specific laboratory safety monitoring was planned given the established safety of the loading dose of 100000IU and weekly dose of 10000IU. AHEs were recorded via electronic questionnaires throughout the study. Participants who reported symptoms suggestive of vitamin D intoxication had a venous blood sampling (total and ionised calcium, phosphorus, alkaline phosphatase, albumin, and creatinine). Any abnormal laboratory value was interpreted as ‘clinically significant’ or ‘not clinically significant’ by the site endocrinologist blinded to study allocation. Further investigation or action for individual participants (including interruption, cessation, or unblinding of the study drug via pharmacy or by analysis of serum 25OHD) was determined by the site endocrinologist, if indicated to ensure participant safety. The AHE’s occurrence was reviewed periodically by the Data and Safety Monitoring Board (DSMB). Code breaking was allowed only if deemed essential for participant management. If relevant, summary reports aggregating (or not if requested) both groups were to be provided to the DSMB.

**Data management and monitoring**

The principal investigator (FMD) and statistical group (SG, RP) oversaw randomisation, data management, progress monitoring and all analyses, including those for the Data Monitoring Safety Board. The DSMB membership included: Lehana Thabane, biostatistician (Chair), Gary Kobinger, infectious disease specialist, Kevin Thorpe, biostatistician, and Edgar Delvin, biochemist and expert in vitamin D. DACIMA was used for online data entry and management.

A combination of remote monitoring activities and in-person routine monitoring visits were conducted by an independent study monitor with the first randomised participants at each site and on a bi-monthly basis, to ensure that each site adhered to the study protocol, Good Clinical Practice guidelines, and data collection completeness.

**Sample size calculation**

Given uncertainties in infection progression, a Bayesian adaptive design was used where the posterior probability of effectiveness, that is, P(OR<1|data) was the basis of inference and decision making. Assuming an expected OR of 0.80 and 1:1 treatment allocation, a total net sample size of 2100 was required to identify a 20% reduction in the risk of COVID-19 in the vitamin D versus control group, with 80% power with the design described above. Considering a dropout rate of 15%, 2414 participants were targeted. An interim analysis was planned when 75% of participants would have reached week 12, at which time the following assessments were to be made: the progression over time in the incidence of infection (slope of the curve of infection) was to be updated and if the probability of effectiveness exceeded 0.95 (p(OR<1)>0.95), the trial would have been terminated for efficacy at the interim point (12 weeks); otherwise, the study would have continued to 16-week follow-up. Simulation results showed that, with the net sample size of 2100 (assuming an expected OR of 0.80 and 1:1 treatment allocation), there was about a 55% chance that the trial would be terminated for efficacy at the interim analysis. The overall infection rate was monitored on a monthly basis: note that the study could have been extended to 24 weeks based on the progress of the infection rate, if required.

**Statistical analysis**

**Primary outcome**

An intention-to-treat analysis was to be carried out with all randomised participants. For the primary outcome, the posterior distribution of the OR of COVID-19 infection (OR) was the basis of inference in interim and final analyses. The posterior distribution of the OR was to be estimated by drawing samples from the posterior risks under each arm, which could be obtained analytically in a β-binomial model. Flat prior distributions were assumed for
the risks ($\beta(1,1)$). Posterior 95% credible intervals were to be reported as interval estimates for the OR. Crude analyses as well as analyses adjusted for important covariates (ie, potential confounders, effect modification and baseline group imbalances) were to be conducted. Subgroup analyses would be conducted on baseline 25OHD, age, sex, BMI, occupational risk and COVID-19 vaccination. A stratified analysis on geographical infection rate would be explored; sensitivity analysis censoring to date of COVID-19 vaccination, would be conducted if applicable.

Secondary outcomes
Distribution of disease severity defined as a five-level ordinal outcome would have been examined with a Bayesian analysis using a proportional odds model; the posterior probability of OR would have been obtained by Markov chain Monte Carlo sampling implemented in Stan. Duration of symptoms, duration of working day absences and of unemployment would have been examined by a zero-inflated Poisson distribution.

ETHICS AND DISSEMINATION
This study was reviewed and approved by the research ethics board (REB) of the CHU Sainte-Justine, serving as the central REB of all participating institutions (MP-21-2021-30/4). A non-objection letter from Health Canada had been obtained to use high-dose vitamin D loading dose as well as the TASSO-SST device for home blood sampling and the NADAL COVID-19 IgM/IgG rapid serology test. Written informed consent for study participation, for biobanking specimens for ancillary studies, and for subsequent publication of results was obtained from all participants, with the knowledge that participation was voluntary and could be withdrawn at any time with no effect on their current/future medical care. As part of the informed consent, enrolees had the option to participate in the HostSeq COVID-19 Canadian biobank conducted under the supervision of CGen, a national Canadian platform for sequencing and genome analysis (online supplemental file 2). In Canada, healthcare is provided to those who suffer harm from trial participation.

All protocol amendments were submitted to Health Canada, investigators and REB; if these changes implied a revision of consent forms, ongoing trial participants were informed of new modifications to provide informed consent. All information obtained during the study were and would continue to be kept confidential as per the law. Data were collected directly by electronic data capture on Dacima Clinical Suite (DACIMA Software, Montreal, Canada). Data safety and confidentiality was upheld at all data collection stages by assigning a unique subject identifier (ID) to each participant, with data and samples kept under lock and key, electronic password protection and access restricted to study personnel. Samples collected during the study were labelled with the unique research code, prior to transfer and storage at the CHU Sainte-Justine biobank, with access restricted to authorized personnel.

This trial used pragmatic patient (irrespective of baseline 25OHD level) and intervention to attempt to maximise subsequent implementation into practice. If the intervention had been shown to be effective in reducing infection and morbidity, this approach would have been readily implementable and could have markedly influenced practice during the COVID-19 pandemic. No participant identifiers were used in the dissemination of this research. Healthcare professionals serving as partners were informed of the study design and pretested all questionnaires.

Results are being disseminated to the medical community via national/international conferences and publications in peer-reviewed journals.

Trial status, challenges and discussion
The study was conducted as per V.1.8 (18 January 2021). The recruitment started on 9 February 2021. On the DSMB recommendation, recruitment was stopped prematurely on 18 March 2021, after 34 participants were enrolled, due to the inability to recruit approximately 200 participants/week required to meet the target sample size of 2415 participants. The DSMB advised that the continuation of the trial, as originally designed, would not be able to answer the research question and recommended that recruitment be stopped for futility. Recruitment difficulties were attributed in part to the high use of vitamin D and high concurrent vaccination rate among our target population, HCWs, the first targeted to be vaccinated from January 2021 onwards. Based on the recommendations of the study’s endocrinologist, a premature end of follow-up after a minimum of 4 weeks from randomisation was deemed sufficient to monitor the safety of the intervention in all participants. The time frame was deemed sufficient to ensure participant safety while learning for the study, that is, transforming the PROTECT Study into a pilot study to document the impact of the study intervention on the rise in vitamin D serum level, participants’ adherence to the study intervention and procedures in the context of a hybrid study, and so on. The last end of visit was conducted on 4 May 2022.

Potential re-directions of the study were discussed. The first option was to change the main outcome for an immunogenicity study in the general adult population. However, after strong consideration of the amount of changes to be made to the protocol and related documents (standards of procedures, case report forms, participant’ instructions and notification, etc), the expected delay in obtaining approval by all regulatory and ethical authorities, the impossible logistic of recruiting participants after the same duration of exposure to the study intervention prior to their vaccination, combined with the government of Quebec announcement that all willing adults would be vaccinated by 24 June 2021, the research team judged that it would be unfeasible to perform a scientific solid and feasible trial on immunogenicity if one could not control
the timing of immunisation, combined with the expected very short recruitment time frame.

A second option that received very strong consideration was to replicate the PROTECT Trial in children aged 9 years and over. Again, after considering changes to be made to the protocol and related documents, the expected delay for obtaining approval by all regulatory and ethical authorities including school boards, combined with the Pfizer-BioNTech announcement that their vaccine was not only 100% successful for preventing COVID-19 infection in adolescents aged 12–15 years, but that they forecast vaccinating teenagers in time for the September 2021 school entry, the Principle Investigator judged that it was unrealistic to aim for the large recruitment target within such a short time frame.

The protocol was submitted for publication after the last patient end-of-study visit, due to the incredible amount of work done to set up and initiate this large hybrid trial. Of note, the hybrid trial was preceded by two pilot studies, each to test a new experimental device that enabled partial or totally remote participation. The pandemic also imposed important sanitary protocols and space restrictions for recruiting on-site potentially COVID-19-infected HCWs, as well as several protocol amendments to facilitate and adjust the trial in the context of emerging science, material shortage, and anticipated vaccination campaign; each amendment in turn required significant modification of all related electronic documents and manual of procedures, and resubmission to obtain regulatory approvals. Collectively, this lead to a delay in recruitment initiation which contributed to the premature end-of-follow-up in enrolled participants.

With the gained experience and knowledge, it is crucial that a future trial must begin fast prior to widespread vaccination and in populations where infection rate is high. Permitting study entry to individuals with prior infection and prior vaccination (given common re-infections and temporary vaccine protection) could have been considered, but it would have significantly reduced the event rate, required prolongation beyond 24 weeks (and additional funding), and compromised study power as was noted in other primary prevention trials. Restricting eligibility to patients with vitamin D deficiency (<25 nmol/L) would have severely interfered with recruitment ability in population-based or HCWs studies. Use of calcifediol (25-hydroxyvitamin D or (25OHD)) may have been associated with more potency and rapid rise in serum 25OHD than expected for cholecalciferol (vitamin D₃) although the choice is debated and rapid access to study drug and matching placebo remains a crucial challenge at the onset of a pandemic. Revisiting the intervention dose and frequency of administration in light of the latest literature on SARS-CoV-2 and related virus could be considered, although current evidence suggest that, with similar doses, high-incidence population may be more important than dosing in primary prevention and high doses are effective in tertiary prevention. Of interest, we have demonstrated that the intervention significantly rose 25OHD levels well above 75 nmol/L, that is, in the hypothesised range for optimal pro-immune and anti-inflammatory impact. A pragmatic design with fewer outcomes and monitoring via administrative databases appeared theoretically more efficient, but required rapid access to data when interim analyses are planned to monitor event rate; any delay in data access could raise serious challenges and hamper trial decisions. Pursuing a hybrid approach to facilitate enrollment in the context of a pandemic was feasible, although electronic self-screening and outcome monitoring required a lot of programming that have contributed to implementation delays.

The publication of this protocol is meant to share our experience, including conducting a hybrid (virtual and/or in-person) trial and lessons learnt, to serve as template to accelerate protocol writing and its improvement in the context of another epidemic/pandemic, and to serve as reference for the publication of our pilot studies that enabled this trial, and lessons learnt from this experience. As vitamin D supplementation has shown a benefit as tertiary prevention in severe COVID-19 cases, with insufficient data to conclude its impact as primary and secondary prevention, this approach remains worthy of testing.

Author affiliations

1 Departments of Pediatrics and of Social and Preventive Medicine, Centre hospitalier universitaire (CHU) Sainte-Justine, University of Montreal, Montreal, Quebec, Canada
2 Microbiology and Infectious Disease, Centre hospitalier universitaire de santé de Montréal (CHUM), University of Montreal, Montreal, Quebec, Canada
3 Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
4 Clinical Research and Knowledge Transfer Unit on Childhood Asthma (CRUCA), Research Centre, CHU Sainte-Justine, Montreal, Quebec, Canada
5 Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada
6 Physiology, McGill University, Montreal, Quebec, Canada
7 Applied Economics, HEC Montreal, Montreal, Quebec, Canada
8 Department of Microbiology, Infectious Diseases & Immunology, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada
9 Department of Medicine, Centre universitaire de santé de Montréal (CHUM), University of Montreal, Montreal, Quebec, Canada
10 Open access

Acknowledgements The authors thank, for collaboration, Danny Germain from Quebec Riva Laboratories who agree to provide free of charge Study Preparations (vitamin D and matching placebo), available in bottles of 60 tablets, allowing for study prolongation. The authors also thank Benoît Hebert of teracero Pharma Inc, for providing free-of-charge the NASAL COVID-19 IgM/IgG Rapid serology test kits, Martin Sauvageau for implementing and coordinating the RT-qPCR analysis of saliva samples at the Montreal Clinical Research Institute, Christian Renaud for coordinating the COVID-19 serology analysis, and Claude Bourassa for coordinating all other blood analyses at the Sainte-Justine University Health Centre. The authors also thank, for collaboration, Raymond Loyer from EFS Solution Santé who adapted their appointment software for the authors’ needs as well as John Padoba, Rabie Razgallah, and Mustapha Gharb who programmed and revised the eCRF to the authors’ needs. The authors thank Anna Smynova for coordinating the development of the eCRF and data management. The authors also thank Catherine Lamontagne from Orokom Communication Marketing who developed the communication strategy and tools and oversaw the publicity campaign with Marie-Line Bénard-Cyr of the CHU Sainte-Justine who also developed the PROTECT website and Laureanne Marceau of the CHUM. The authors also thank the members of the Data Monitoring Safety Board namely Lehana Thabane (Chair), Gary Kobinger, Kevin Thorpe and Edgar Delvin.
Contributors FMD designed the study protocol, secured funding, and oversaw the overall conduct of the project. CT contributed to the protocol and amendments, directed the study implementation at the CHUM, and coordinated the prescription of study drug, pharmacy dispensing, as well as salivary sample collection and interpretation. SG conceived the statistical approach and sample size calculation and along with RWP, oversaw randomisation and statistical analysis. CL, JHW and CQ contributed to the study design and amendments. BH wrote the first manuscript draft. LSSM oversaw the safety assessment. DC is responsible for the work absenteeism analysis. All co-authors approved the manuscript. Authorship eligibility on resulting manuscripts will follow standard guidelines.

Funding This study is funded by a grant awarded through a peer-reviewed process of the COVID-19 May 2020 Rapid Response Funding Opportunity by the Canadian Institute of Health Research, 160 Egin Street, Ottawa, ON K1A 0W9, Canada (grant number #447317).

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Consent obtained directly from patient(s).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. After publication of the primary results, the data sets used and analysed during the current study will be made available by the corresponding author on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been reviewed. This content is therefore not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Francine Monique Ducharme http://orcid.org/0000-0001-5096-0614
Banafsheh Hosseini http://orcid.org/0000-0002-3962-2777

REFERENCES
32. Vieth R, Holick MF. Chapter 57B - the IOM—endocrine society controversy on recommended vitamin D targets: In support of the
<table>
<thead>
<tr>
<th>Section/item</th>
<th>ItemNo</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>N/A</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>8 (line 138)</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>1, 25, supplemental funding file</td>
</tr>
<tr>
<td>Roles and</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1, 26-27</td>
</tr>
<tr>
<td>responsibilities</td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>1, 26</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>26</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Background and rationale 6a</td>
<td>Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6b</td>
<td>Explanation for choice of comparators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Objectives 7</td>
<td>Specific objectives or hypotheses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trial design 8</td>
<td>Description of trial design including type of trial (e.g., parallel group, crossover, factorial, single group), allocation ratio, and framework (e.g., superiority, equivalence, noninferiority, exploratory)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methods: Participants, interventions, and outcomes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study setting 9</td>
<td>Description of study settings (e.g., community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Component</td>
<td>Sub-component</td>
<td>Description</td>
<td>References</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td></td>
<td>Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)</td>
<td>9, 10</td>
</tr>
<tr>
<td>Interventions</td>
<td>11a</td>
<td>Interventions for each group with sufficient detail to allow replication, including how and when they will be administered</td>
<td>10, 11</td>
</tr>
<tr>
<td></td>
<td>11b</td>
<td>Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>11c</td>
<td>Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)</td>
<td>17, 18</td>
</tr>
<tr>
<td></td>
<td>11d</td>
<td>Relevant concomitant care and interventions that are permitted or prohibited during the trial</td>
<td>10</td>
</tr>
<tr>
<td>Outcomes</td>
<td>12</td>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended</td>
<td>11, 12</td>
</tr>
</tbody>
</table>
Participant timeline  
13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure 15, 16, 17, 18, Figure 1).

Sample size  
14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 20-21.

Recruitment  
15 Strategies for achieving adequate participant enrolment to reach target sample size 12,13.

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation  
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 11.

Allocation concealment mechanism  
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 11.
Implementation 16c  Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions

Blinding (masking) 17a  Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how

17b  If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods 18a  Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

18b  Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
### Data management

19. Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.

### Statistical methods

20a. Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.

20b. Methods for any additional analyses (eg, subgroup and adjusted analyses).

20c. Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation).

### Methods: Monitoring

Data monitoring

21a. Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed.
<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
</tr>
<tr>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
</tr>
<tr>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
</tr>
</tbody>
</table>

### Ethics and dissemination

<table>
<thead>
<tr>
<th>Sub-item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research ethics approval</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
</tr>
<tr>
<td>Protocol amendments</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
</tr>
<tr>
<td>Consent or assent</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
</tr>
<tr>
<td>Additional consent provisions</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
</tr>
</tbody>
</table>
How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial.  

Financial and other competing interests for principal investigators for the overall trial and each study site.  

Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators.  

Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation.  

Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions.  

Authorship eligibility guidelines and any intended use of professional writers.  

Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code.
<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent materials</td>
<td>Model consent form and other related documentation given to participants and authorised surrogates</td>
<td>Supplementary file 2</td>
</tr>
<tr>
<td>Biological specimens</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
<td>Supplementary file 2</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.*
INFORMATION AND CONSENT FORM

Project Title: Prevention of COVID-19 with Oral Vitamin D supplemental Therapy in Essential healthCare Teams (PROTECT)

Protocol Number: PROTECT 2020

- **Principal investigators at CHUSJ:** Dr. Francine M. Ducharme, MD, FRCPC, Paediatrician, Centre hospitalier universitaire Sainte-Justine (CHUSJ)
- **Principal investigator at the CHUM:** Dr. Cecile Tremblay, MD, FRCPC, Microbiologist/Infectiologist, Centre hospitalier universitaire de Montréal (CHUM)

**Co-investigators:**

- Decio Coviello, health economist, Hautes-Études Commerciales, University of Montreal
- Shirin Golchi, biostatistician, McGill university
- Cristina Longo, epidemiologist, University of Montreal
- Robert Platt, biostatistician, McGill University
- Caroline Quach, MD, Paediatrician microbiologist, CHUSJ
- Christian Renaud, pediatric microbiologist, CHUSJ
- John White, biochemist, McGill University

**Co-investigators at the CHUM:**

- Dr. Louis-Georges Sainte-Marie, MD, endocrinologist, CHUM
- Dr. Emil Toma, MD, Dsc, FRCPC,CHUM

**Industrial Collaborators:** Laboratoires Riva, Blainville, Quebec

**Funding source:** Canadian Institutes of Health Research (CIHR), in the context of the COVID-19 Rapid Research Funding Opportunity

**Multicenter identifier:** MP-21-2021-3044
**CHUM project number : 20.319**
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS STUDY?

Today, we are inviting you to participate in this research study because you are a healthcare worker who is working in a high COVID-19 incidence area and in a setting with a high risk of contact with COVID-19 infected cases. Please read this information to help you decide if you want to participate in this research project. It is important that you understand this information. We encourage you to ask questions. Please take all the time you need to make your decision. You may also want to discuss this study with your family doctor, a family member or a close friend.

WHY IS THIS STUDY BEING DONE?

During the current COVID-19 pandemic, many healthcare workers are working in an environment which increases their probability of contracting this viral infection. Healthcare workers are more frequently infected than the rest of the population. Infected healthcare workers can infect their family, their patients, and their contacts. In addition to being withdrawn from work, they could have transmitted the disease to other colleagues, which further impedes our ability to deliver care to the population.

Vitamin D supplementation can decrease the risk of having the common cold, but it is not known if it could have an effect on the COVID-19 infection. Vitamin D is produced in our bodies from exposure to the sun and can be obtained from supplements and certain foods. However, many Canadians do not have an adequate intake of vitamin D throughout the year.

However, studies testing supplementation with other seemingly harmless vitamins, such as beta carotene and vitamin E, have shown unexpected important adverse reactions. Therefore, it is necessary to properly assess the benefits and the potential unexpected adverse reactions in the context of a clinical study.

This study will investigate whether a high-dose vitamin D supplementation could reduce the risk and severity of COVID-19 infection and work absence in healthcare workers.

HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?

We will be recruiting 2414 graduate healthcare workers, men and women, aged 18 to 69 years old, actively working and scheduled to continue working in a setting at high-risk of contact with people infected with COVID-19 and are working in high COVID incidence areas.

WHAT DOES THE STUDY INVOLVE?

If you agree to participate in this study, you will be assigned by chance to one of two groups. One group will receive one dose of 100,000 IU of vitamin D by mouth at the first visit and then take at home 1 pill of 10,000 IU of vitamin D once a week. The other group will receive a placebo dose at the first visit and then a placebo pill once a week. The vitamin D supplement is the active substance, meaning it could have an effect in the body. A placebo is an inactive substance, meaning it has no effect in the body. A placebo is used in clinical studies, such as this one, to ensure that observed changes are due to the active treatment and not to chance. You will have an equal chance of being assigned to each
group. The placebo and the vitamin D supplement look and taste exactly the same, so no one will know which treatment you are given, including the people involved in the study. In this informed consent form, we will use “Study supplement” to refer either to the vitamin D or the placebo.

This study should last 16 weeks and involves two visits. But prior to the first visit, we will conduct a screening/enrolment visit remotely by videoconferencing (or phone). If eligible and consenting, there will be a randomisation visit and an end-of-study visit, the latter two could be conducted in-person or remotely by videoconferencing, at your preference. Because of the pandemic, we wish to reduce the need and/or length of any in-person visit by doing as much as possible remotely.

Note that the study could finish earlier or be prolonged to 24 weeks, depending on the evolution of the pandemic. We ask that you don’t change your usual diet or intake of vitamin supplements (if any) during the study.

**Screening/Enrolment** (pre-visit: about 45-60 minutes)

- We will review the eligibility questionnaire you have completed online, complete it with additional questions, explain the study in detail, and answer your questions.
- If eligible and consenting, you will be asked to sign the consent form, complete a few short study questionnaires and provide your contact information.
- We will ask you questions about your demographics (household, ethnicity), work-related activities and personal health (weight, height, skin color, smoking, medication, vitamins, supplements, health problems).
- To enable the creation of a medical and research pharmacy records, obtain information on COVID test, and ensure optimal contact with you throughout the study, we will ask personal information namely your RAMQ number, names (yours, your parents, your spouse), any drug allergy, your employee number (or practice number for physicians), your postal and email addresses, phone numbers and that of a next of kin and your preferred means to reach you.
- We could show you videos of key procedures (e.g. home blood collection) to help you chose your preferred type of randomisation visit.
- We will schedule the randomisation visit at a mutually convenient time and place given your choice of in-person or remote visit by videoconferencing. However, in case of a suspected prior COVID-19 infection, we would prefer you do an in-person visit to perform a rapid screening test for COVID-19 antibodies.

**Randomisation visit (First visit: Week 0)**

During the visit, which will last approximately an hour,

- If not already done, we will ask you to sign the consent forms, complete missing study questionnaires and your contact information.
- We will take a venous blood sample of about 15 mL (3 teaspoons) to measure the level of vitamin D, look for COVID-19 antibodies and to do an optional genetic analysis to examine a possible genetic predisposition to respond to vitamin D and to severity of COVID-19 symptoms.
We would like to obtain a small drop of blood either from the venous puncture or via a finger-prick to look for COVID-19 antibodies in your blood using NADAL® COVID-19 IgG/IgM Rapid Test: if positive, you would not be eligible for this study. This test is not yet licensed for use in Canada and its use in this study is investigational. It has been selected for use prior to enrolment because it provides antibody results in 15 minutes. The results of this investigational test will be shared with you, acknowledging the risk of false positive or negative results. They will also be subsequently compared to the approved (Liaison IgG COVID-19) serology test.

We will show you how a video on the TASSO home blood sampling kit at home for the last visit; if interested, we will show you how to use it, identify your sample, package it, and send it back to us (see below under First Remote visit). This device is not yet licensed for use in Canada and its use in this study is investigational. However, we have successfully pre-tested it and have validated the concordance between test results obtained with the TASSO and venous sampling.

We will show you how to take a saliva sample by spitting into a tube. You will receive a pamphlet with instructions and could watch a video. You should not brush your teeth, eat, drink, smoke or chew gum for 30 minutes before spitting a small volume of saliva (2 mL). If you prefer to do an oro-nasopharyngeal sample, you would need to insert a swab (a small tube with a cotton tip) into the back of your mouth, then in one of your nostrils gently rotating the swab for about 5 seconds. We will ask you to take the saliva (or oro-nasopharyngeal) sample under our guidance. We will then show you how to identify it with our prepared labels, record the date and time, package it, and sent it back for analysis for COVID-19, and possibly other viruses and cells.

You will be asked to take ten (10) pills of the Study supplement at this first visit only in front of the research personnel (in person or by videoconference). You will take home the bottle of Study supplement and be asked to take one (1) pill once a week until the end of the study.

We will send you by text message or email as per your preference, a first reminder with a link to a questionnaire to confirm that you have received it and are able to complete and submit the brief questionnaire. The same approach will be used every week.

We will give you all the other study materials including the saliva collection tube pre-printed labels, biohazard bags, insulated envelopes or boxes for shipment, prepaid courier waybills, and if you are interested in a Remote end-of-study visit, the TASSO home blood collection kit. It is possible that we ask you to use the NADAL® COVID-19 IgG/IgM Rapid Test at the last visit for validation purposes.

For participants choosing to have a Remote First Visit, in whom there is a suspicion that you may have had a prior undiagnosed COVID-19 infection in the past, we would prefer that you come for an in-person visit. Alternatively, we may send you first a finger-prick test kit to look for COVID-19 antibodies in your blood; if so, we would ask that you use it on your fingertip in front of us by videoconference. If positive, you would not be eligible for this study. If negative, the Study supplement and required materials would then be sent to the participant’s home prior to the randomisation visit. We will ask you to take in front of us by videoconference, the Study supplement, the saliva sample, as well as the blood test and 2nd optional saliva sample (for genetic analysis).
We will show you how to take a small sample (<1 mL) of capillary blood, using a blood collection kit specifically conceived for home collection, called TASSO-SST OnDemand. This device is not yet licensed for use in Canada and its use in this study is investigational. However, we have successfully pre-tested it and have validated the concordance between test results obtained with the TASSO and venous sampling. We will ask you to watch a short video and read the brochure explaining the procedure, then ask you to use it under our guidance. Briefly, you will need to warm the skin of your upper arm by rubbing it for about 45 seconds, disinfecting it, applying the little device on your arm, pressing on a button that will puncture a very small hole in the skin, then leave the device in place for about 5 minutes while blood flows slowly in a small tube. As only a small sample of blood can be obtained, it is very likely that we ask you to repeat this with a second kit. We will show you how to remove the small tube, close it with a small cap, identify the sample with our prepared labels, record the sampling date and time, package it, and prepare it to be sent for analysis for vitamin D and COVID-19 antibodies. We will ask your feedback on this type of blood collection method.

If you wish to participate in the optional genetic analysis, we will ask you to collect 2 mL of saliva in another small tube (as the blood sample made by TASSO is not enough for this analysis), identify and date the sample with our prepared labels, and send it to us.

Between visits

- For the following weeks 0 to 16 (or later, should the study be extended up to 24 weeks) participants will take every week one (1) Study pill.
- You will receive a message via email or text message, according to your indicated preference, to remind you
  - Once a week to take the Study supplement
  - Once every two weeks to take the Study supplement, and fill out the brief electronic questionnaire (duration of 3-5 minutes) regarding your health and work status in the previous 2 weeks.
  - At any point in time if you have symptoms, to complete the daily symptoms diary (duration of 1-2 minutes) until 48 hours after the resolution of symptoms. If you have symptoms that should prompt testing for COVID-19, as listed on the cv19quebec.ca website, we will ask you to contact your health office for this purpose.
- If there is no response from you within a few days of sending the electronic questionnaire, we will contact you; if there is still no response from you within 7 days of us sending the electronic questionnaire, we will contact your next-of-kin indicated by you.

If you are infected during the study

If we obtain a positive COVID result from one of your saliva (or oro-nasopharyngeal) samples, you will be notified by a Study team member, by the preferred communication means you have indicated (phone, text message or email). As all positive results will be reported to the public health authorities you will be contacted as soon as possible by them for an assessment and instructions.
If you receive a positive COVID result from a test done outside this study (i.e., for clinical reasons), we ask that you inform us immediately and to indicate it in the follow-up questionnaire.

At the reception of a positive COVID test result,

- We will ask you to complete the daily diary of symptoms (duration of 1-2 minutes)
  - Until 48 hours after resolution of symptoms
  - Or if you remain asymptomatic, for a minimum of 14 days;
- If symptoms reappear, we will ask you to restart documenting them in the daily diary of symptoms
  - Until 48 hours after resolution of symptoms;
- If your symptoms continue beyond 14 days, we will ask you to complete the weekly diary of symptoms (duration of 1-2 minutes), once a week, until resolution of symptoms
- We will ask you to continue taking your weekly supplement and completing the follow-up questionnaire once every two weeks.

In case of an imminent vaccination against COVID-19

- If you expect to receive a vaccine against COVID-19 in the next few weeks, we will ask you to notify us immediately or via the questionnaire every two weeks.
  - We will rapidly organise a visit in person or remotely, before the scheduled date of the vaccination, to obtain a saliva sample to test for COVID-19 infection and a blood sample either in your vein (9 mL) or with the TASSO device at home to look for COVID-19 antibodies and level of vitamin D prior to the vaccination.
  - Just before, and about 1 month after, your second vaccine dose against COVID-19, we will ask you for another blood sample either in your vein (4.5 mL) or with the TASSO device at home to look for COVID-19 antibodies.
- We will ask you to continue
  - Once a week to take the Study supplement
  - Once every two weeks to fill out the brief electronic questionnaire (duration of 3-5 minutes) regarding your health and work status in the previous 2 weeks.
  - At any point in time if you have symptoms, to complete the daily symptoms diary (duration of 1-2 minutes) until 48 hours after the resolution of symptoms. If you have symptoms that should prompt testing for COVID-19, as listed on the cv19quebec.ca website, we will ask you to contact your health office for this purpose, whether you have been vaccinated or not.

End-of-study – Week 16 (or later if the study is prolonged)

At the end of the study, you will be invited to a last in-person or remote visit. This research visit will take approximately 30 minutes and involve the following:

- You will be asked to return the Study supplement bottle containing the unused pills.
A venous (or capillary blood if done remotely) sample and, if you have not tested positive at COVID-19 before, a saliva (or oro-nasopharyngeal) sample will be collected.

A rapid COVID-19 antibody test (NADAL®) may also be done on a blood drop (finger-prick or from the venous puncture) for validation purposes. If done remotely, this test may be done on blood sampled by finger-prick under our guidance by videoconference.

You will complete the last few short study questionnaires and any missing information in the previous ones, if applicable.

If conducted remotely, the samples, Study supplement bottle and unused material should also be shipped to the Coordinating Center.

**Collecting information on COVID-19 tests made for clinical reasons**

The results for a COVID-19 test performed for clinical reasons outside this study will be documented by you in the follow-up questionnaire (*faster means to inform us*) as well as in your institution’s (Pandemic) or provincial database of COVID-19 cases, namely Trajectoire Santé publique (TSP) including all individuals who tested positive and all healthcare workers who tested positive under the supervision of the Ministère de la santé et des services sociaux (MSSS). If you are unable to answer the follow-up questionnaires, the information documented in these databases would ensure that we have complete information on the primary outcome of the study and thus allow us to determine accurately the impact of the intervention on the risk of infection with COVID-19.

**Collecting information on healthcare services**

The date, diagnosis, type of professional and of health care services which you have received during medical visits and hospitalisations will be obtained from the administrative databases of the Régie de l’assurance maladie du Québec (RAMQ) and Quebec hospital discharges (MED-ECHO). This will allow us to accurately determine the impact of the intervention on the severity of COVID-19 infection and other concomitant illnesses.

**Collecting information of work absence**

The number of days of work absence, overall, by type (i.e., holiday, illness, etc.), and specifically due to COVID-19, including absences due to an infection acquired at work or outside of work, preventive withdrawal due to pregnancy or other health conditions, awaiting test results/investigation, or other reason for quarantine will be collected from you via the follow-up questionnaire (*faster and most detailed means*), as well as from your institution’s Direction of Health Resources or, if you are an attending physician, from the Direction of professional services. If you are unable to answer the follow-up questionnaires, the information documented in these databases would ensure that we accurately ascertain the impact of the intervention on work absences.

**BIOBANK**

For the purposes of this study, we will keep the biological samples collected (blood, saliva and/or oro-nasopharyngeal) in a biobank as well as the clinical and administrative data collected during the course of this study in order to complete the study’s objectives, and to
conduct research on vitamin D, COVID-19 and its treatments and other related diseases. We would like to quantify specific cellular receptors which allow entry of COVID-19 into cells (for example, the angiotensin converting enzyme-ACE2) and inflammatory markers (such as the C-reactive protein). The collected samples will be kept in a biobank in the Research Center of CHU Sainte-Justine under the supervision of Dr Francine M. Ducharme. The samples will be kept as long as the research team can guarantee their proper management. Confidentiality of the identity of the samples will be guaranteed by assigning them a specific code. Your sample will not be identified by your name and cannot be used to identify you directly. After 5 years, the code key will be destroyed, and the samples will become completely anonymous. Your samples could possibly be shared with other researchers in other institutions. However, the access to data will only be allowed for approved projects by an independent research ethics board.

GENETIC ANALYSIS (optional)

Each person has their own set of unique genes or “genome”. Genetic research aims to determine if there are genetic predispositions which make you more susceptible to a COVID-19 infection, to respond to vitamin D, to modulate disease severity and the interaction of these factors.

If you accept to participate in the genetic analysis, these analyses will be done on a small part (4 mL) of the venous blood sample provided during the first visit. If you decide to participate remotely, we will ask you to provide a saliva sample in a small tube.

We would like to sequence your entire genome and conduct gene expression analyses. We would also like to share your genetic data as well as other collected clinical data during the PROTECT study with the Canadian database Hostseq COVID-19 for use for COVID-19 related research and other aspects of human health. This biobank will serve as a centralized resource in Canada for COVID-19 research and other health-related studies. The data in the HostSeq database are under the supervision of CGen, a national Canadian platform financed by the federal government for sequencing and genome analysis. The principal investigators of the PROTECT study as well as the administrators of the Hostseq biobank COVID-19 will share your genetic and clinical information with other Canadian and international researchers whom are approved by CGen (the sponsor). The data could also be used for commercial use. However, your data will not be shared with until after an examination by a data access committee. This committee will verify that the use of the proposed research is in line with the objectives of the database HostSeq and that the research team which requests access has already been granted the required approval in accordance in terms of research ethics requirements. Approved researchers will sign agreements. These agreements will control how the data will be used. Individual results of any research conducted using your samples or any individual incidental findings will not be shared with you, as the research conducted on your data will have no individual diagnostic or therapeutic significance to you.

WHAT ARE THE BENEFITS AND RISKS OF THIS STUDY?

Version 1.8a 2021-01-18

8/15
Benefits:

You may not benefit directly from the study intervention if it is not efficacious or if you have been assigned in the placebo group. However, the screening may identify earlier an active or past COVID-19 infection that was not apparent. Your participation will help advance our knowledge on vitamin D and on the prevention of COVID-19 infection in healthcare workers and other individuals at risk of infection.

Each positive COVID-19 result from the saliva (or oro-nasopharyngeal) or blood sample will be shared with you according to your preferred way of communication: telephone, text message or email. All positive saliva (or oro-nasopharyngeal) results will also be shared by the Microbiology Laboratory of CHUM with the Public health authorities and will be added into your file at the CHUM and Dossier Santé Québec. No other research result will be provided to you. Research findings resulting from your participation to this study could potentially contribute to creating commercial products from which you would not be able to claim any financial benefit.

Risks:

• **Related to study medication:**

The vitamin D dose used in this study has been shown to be safe in adults. This dose is approved by Health Canada for the purpose of this study only, but not for clinical use yet. It is unlikely that you will have any side effects because of the amount of vitamin D used in this study as when combining the first and weekly doses, the total remains below the maximum amount allowed.

However, we will ask you to notify us immediately if you have any of the following, as they could be signs of an acute excess intake of vitamin D: mainly, a marked increase in thirst or an increase in the volume and frequency of urination (with or without fatigue, loss of appetite, nausea or vomiting, headaches, drowsiness, cardiac arrhythmias, constipation, muscle or bone or chest pain, mouth dryness or a metallic taste).

Later signs and symptoms that may indicate a chronic excess intake of vitamin D are: a marked increase in thirst, an increase in the volume and frequency of urination including during the night, loss of appetite, weight loss, red eye or conjunctivitis, inflammation of the pancreas, light sensitivity, runny nose, itching, fever, reduced libido, kidney stones, increased concentration of some analytes in the blood (BUN, AST, ALT, cholesterol), or in urine (albumin), ectopic calcification, hypertension, cardiac arrhythmias and rarely, a psychosis.

It’s possible that other currently unknown risks are associated with Vitamin D intake.

One of the reasons we collect a blood sample is to measure the concentration of vitamin D in the blood at the start and end of the study. this will allow us to see if the vitamin D blood level is linked to the number and severity of COVID-19 confirmed cases.

• **Related to study procedures:**
The salivary collection sample is painless. If done, an oro-nasopharyngeal swab may cause slight discomfort during collection that will subside after its removal. The side effects of having blood collected by venous puncture or TASSO can include bleeding, bruising, discomfort and pain at the sample site. It is possible that the NADAL COVID-19 IgG/IgM Test may give false positive or false negative results. In case of divergence of results, we will communicate to you the results of the approved IgG test when available.

• Related to confidentiality:

There is always a small risk that your data could one day be re-identified. The genetic information is unique to each person, just as your fingerprint. This means that theoretically, you could be identified using your genetic code; however, this is not easy to do. Considering the advances in technology, there could be new ways to link you to data that we have not foreseen today, despite the strict confidentiality measures in place. Possible re-identification or unintentional disclosure of your genetic and clinical research data could lead to a loss in confidentiality and a possible future discrimination against yourself or your biological parents. But all security measures will be put in place to protect your privacy.

WHAT ARE THE COSTS OF TAKING PART IN THIS STUDY?

The Study supplements are provided free of charge by the manufacturer, Laboratoire RIVA.

WHAT ARE THE OTHER FINANCIAL ASPECTS?

For each completed visit (0 and 16 weeks), you will receive a $25 check by mail to compensate for your time. The check may arrive at your home between 4 and 8 weeks after the visit.

HOW IS PRIVACY INSURED?

During your participation in this research study, the investigators responsible for this study as well as the members of their research team will collect, in a research file, the required personal information to answer the scientific objectives of this research project.

These information could include your demographic data (name, sex, date of birth, ethnic origin, weight and height), your past and present health status, your health-related habits, medication you take, your work absences, and the results of all tests, exams, and procedures which you will participate in. Your personal file will include your address, email, telephone numbers, RAMQ number, and employee or practice number be kept in a separate file with restricted access; this information is required to create a medical and pharmacy file at the CHUM and for communication purposes during the study.

The coded blood, saliva (and/or oro-nasopharyngeal) samples will be sent to the biobank located at the Research Center of CHU Sainte-Justine under the supervision of Dr Francine M. Ducharme. The coded results of completed analyses will be kept on a protected server with restricted access at DACIMA company during the study, and thereby transferred to a secure server with restricted access in the Research Center of CHU Sainte-Justine under the supervision of Dr Francine M. Ducharme. During the study, the personal information...
used to arrange virtual and in-person study visit appointments will be kept on a protected server with restricted access at the company providing the appointment-making software. Following the conclusion of the study, this information of yours will be transferred to a secure server with restricted access in the Research Center of CHU Sainte-Justine under the supervision of Dr Francine M. Ducharme. The database of HostSeq will be kept on secure cloud servers (online) that are based in Canada and will be indefinitely kept or until they are not useful for research.

To ensure your privacy, a copy of the consent form as well as the results to the diagnostic tests required for conducting the research project, will be copied in the research and medical file of the CHUM. Therefore, each person or company which you authorize to consult your medical file, will have access to this information.

The research data will be kept for at least 25 years by the principle investigator. The data collected could be published or discussed during scientific meetings, but it would not be possible to identify you.

All collected information will remain confidential within the limits provided by law. You will only be identified by a code number. The key to the code linking your name to your research file will be kept by the investigator responsible for this research project.

To ensure your safety, a copy of the consent form as well as the results of the diagnostic tests required for research purposes will be placed in the research file and the medical file of the CHUM. Consequently, any person or company to whom you give access to your medical file will have access to this information.

Research data will be kept for at least 25 years by the investigator responsible for this research project. Research data may be published or be the subject of scientific discussion, but it will not be possible to identify you.

For the purposes of surveillance, control, safety and marketing of the Study drug, your research as well as your medical files could be consulted by a person mandated by a regulatory organization, in Canada or elsewhere, such as Health Canada, as well as sponsor representatives of the company manufacturing the vitamin D pills for this project (Laboratoire RIVA), the institution or research ethics committee. These people and organizations adhere to a strict confidentiality agreement.

You have the right to consult your research file to verify the collected data and to correct them, if needed. Moreover, access to certain information before the end of the study could mean your removal from this study in order to maintain the study’s integrity.

**IS YOUR PARTICIPATION VOLUNTARY?**

Yes. Taking part in this study is voluntary. You may choose not to be in this study. You can decide to stop being in the study at any time, without needing to provide any reason, but simply informing the research team.
Your decision to refuse participation or to stop participating in the study at a later time, will have no effect on the quality of care or services to which you are entitled or on your relationship with the people that provide them.

The principal investigators of this study, the research ethics board, the funding agency or the sponsor could decide to end your participation in the study without your consent. This could happen if there are new information or findings that indicate your participation is no longer in the best of your interests, or if you have not been following the study instructions as explained, or if there are other administrative-related reasons to stop the project.

If you stop participating in the study or if you have been removed from it, the collected information and material already received will be kept (as well as the data pertaining to healthcare services and work absences will continue to be collected) and analysed to ensure the validity of this project, unless you specifically ask for them to be destroyed. If this is the case, these data and/or material will be removed from the biobank provided that the code key (linking between nominal data and the study code) is still available, that is, up to 5 years after the end of the study.

If you decide to drop out of the HostSeq database, your data will no longer be shared, and no new data will be collected. The data already in the HostSeq database will be destroyed once informed about this decision. However, it could be impossible to remove the results once they have been compiled with the results of other participants or if they have been published. Moreover, if certain data have been shared with other researchers, it could be possible not to be able to remove this part of the data. In such a case of unsuccessful withdrawal from the study, your identity will always be protected.

All new information acquired during the course of the study which could have an impact on your decision to continue participation will be shared with you rapidly, which is the reason why we would like to keep your personal information and have your approval to communicate with you after the end of the study (optional).

WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?

If you have any questions about the research project or if you have any problems that you believe are related to your participation in the project, you can call the researchers responsible for the project:

- Dr. Francine M. Ducharme at 514 345 4931, extension 4398
- Dr. Cecile Tremblay at 514 890-8000, extension 14645
If you would like information about your rights related to your participation in the research, you may contact the Ombudsman - complaints and quality services of the CHU Sainte-Justine at 514 345-4749, of the CHUM at 514 890-8484 or your CISSS/CIUSSS:

- CIUSSS de l’Est-de-l’Île-de-Montréal : 514 252-3510
- CIUSSS de l’Ouest-de-l’Île-de-Montréal : 514-989-1885, extension 1010
- CIUSSS du Centre-Sud-de-l’Île-de-Montréal : 514 593-3600
- CISSS de la Montérégie-Est : 450-468-8447
- CISSS de la Montérégie-Centre : 450-466-5434

RESEARCH ETHICS COMMITTEE

The Research Ethics Board of CHU Sainte-Justine has approved this study and will continue to monitor it for all participating institutions of the Quebec Health and Social Services network.

LIABILITY

This research is not funded by a private industry. In case of side effects resulting from the study medication or from procedures required for this research project, you will receive all necessary medical care covered by the Quebec’s provincial health insurance plan (RAMQ) or by your private drug insurance plan. You will be responsible for paying the portion of any costs not covered.
CONSENT FORM

Research project title: PRevention of COVID-19 with Oral Vitamin D supplemental Therapy in Essential healthCare Teams (PROTECT)

The nature and procedures of this research project were explained to me. I have read the information and consent forms and I kept a copy, or a copy has been provided to me. I was able to ask my questions and they were answered to my satisfaction. After consideration, I agree to participate in this research project.

I authorize the research team to consult the collected data about me in the COVID infection database (Pandemic) of my institution and/or the provincial TSP database, the medical and hospitalisation services database (RAMQ and MED-ECHO), and the workplace absenteeism database (Human Resources Directorate or Professional Services Directorate) to obtain information that is pertinent to this project.

By agreeing to participate in this study, you are not waiving any of my rights under the law. You are not releasing the investigators from their legal and professional liability.

Name of participant (Print)    Signature   Date

1. I consent to the analysis of gene expression and the sequencing of the whole genome of my coded biological material (blood, saliva, and/or oro-nasopharyngeal). The whole genome sequence could be hosted in the Canadian HostSeq COVID-19 biobank and linked to a database containing the viral genome. This would serve to explore any genetic predisposition to COVID-19, the severity of the disease and response to vaccine.
   □ Yes _________ (Initials)   □ No___________ (Initials)

2. I consent to prolonging the access to my coded data on healthcare use, COVID-19 infections and work absenteeism for 12 months following the study end date, to explore the long-term impact of COVID-19 infection and vaccination.
   □ Yes _________ (Initials)   □ No___________ (Initials)

3. I consent to being contacted to update my personal information, obtain additional information about my health or to be invited to participate in new research.
   □ Yes _________ (Initials)   □ No___________ (Initials)

4. In case I receive a vaccine against COVID-19 during the study, I agree to do the blood samples before the first and second vaccine dose as well as 1 month after the 2nd vaccine dose, even if these samples were to be done after the end-of-study's visit planned at week 16 (or 24).
   □ Yes _________ (Initials)   □ No___________ (Initials)

Participant’s signature: ______________________________

Version 1.8a  2021-01-18   14/15
I have explained the research study and the terms of this information and consent form to the research participant, and I answered all his/her questions. I explained that participation in a research project is free and voluntary and could be stopped at any time they choose.

Name of person obtaining consent (Print)  Signature   Date

(FOR THE CHUM PARTICIPANTS ONLY)

COMMITMENT OF THE PRINCIPAL INVESTIGATOR AT THE CHUM

I certify that this information and consent form was explained to the research participant, and that the questions the participant had were answered.

I undertake, together with the research team, to respect what was agreed upon in the information and consent form, and to give a signed and dated copy of this form to the research participant.

Name (Print)    Signature of the principal investigator at the CHUM    Date